miR‑449c inhibits migration and invasion of gastric cancer cells by targeting PFKFB3

Chen,Xin; Wang,Anping; Yue,Xinxia

doi:10.3892/ol.2018.8609

miR‑449c inhibits migration and invasion of gastric cancer cells by targeting PFKFB3

Authors:
- Xin Chen
- Anping Wang
- Xinxia Yue
View Affiliations

Affiliations: Department of Digestive Disease, People’s Hospital Xinjiang Autonomous Republic, Urumqi, Xinjiang 830001, P.R. China, Department of Anesthesia, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Digestive Disease, People’s Hospital Xinjiang Autonomous Republic, North Hospital,Urumqi, Xinjiang 830001, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/ol.2018.8609
Pages: 417-424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs) are important regulators in the development and progression of human gastric cancer (GC). However, the expression and biological function of miR‑449c in GC remains unknown. In the present study, miR‑449c was demonstrated to be downregulated in GC tissues and cell lines compared with normal. Decreased miR‑449c levels were associated with poor prognosis in GC patients. Overexpression of miR‑449c inhibited migration and invasion in SGC‑7901 cells, while inhibition of miR‑449c enhanced migration and invasion in MGC‑803 cells. Furthermore, 6‑phosphofructo‑2‑kinase (PFKFB3) was identified to be a downstream target of miR‑449c in GC cells. miR‑449c directly regulated the expression of PFKFB3 in GC cells. Overexpression of PFKFB3 abrogated the inhibitory effect of miR‑449c on the migration and invasion of GC cells. In conclusion, the present study suggests that miR‑449c may be a novel biomarker and potential therapeutic target in GC.

View Figures

View References

1	Rugge M, Fassan M and Graham DY: Epidemiology of gastric cancer. Gastric Cancer Springer. 23–34. 2015. View Article : Google Scholar
2	Chang WJ, Du Y, Zhao X, Ma LY and Cao GW: Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
4	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ameres SL and Zamore PD: Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488. 2013. View Article : Google Scholar : PubMed/NCBI
6	Dong H, Lei J, Ding L, Wen Y, Ju H and Zhang X: MicroRNA: Function, detection, and bioanalysis. Chem Rev. 113:6207–6233. 2013. View Article : Google Scholar : PubMed/NCBI
7	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wen D, Danquah M, Chaudhary AK and Mahato RI: Small molecules targeting microRNA for cancer therapy: Promises and obstacles. J Control Release. 219:237–247. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhao X, Dou W, He L, Liang S, Tie J, Liu C, Li T, Lu Y, Mo P, Shi Y, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372. 2013. View Article : Google Scholar : PubMed/NCBI
11	Miao LJ, Huang SF, Sun ZT, Gao ZY, Zhang RX, Liu Y and Wang J: MiR-449c targets c-Myc and inhibits NSCLC cell progression. FEBS Lett. 587:1359–1365. 2013. View Article : Google Scholar : PubMed/NCBI
12	Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, et al: The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 66:1012–1021. 2017. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Adams BD, Kasinski AL and Slack FJ: Aberrant regulation and function of microRNAs in cancer. Curr Biol. 24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
15	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. MicroRNA Cancer Regulation Springer. 1–20. 2012.
16	Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA II, Klarer AC, Redman R, Miller DM, Trent JO, et al: Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 12:1461–1470. 2013. View Article : Google Scholar : PubMed/NCBI
17	Imbert-Fernandez Y, Clem A, Clem B, Tapolsky G, Telang S and Chesney J: Suppression of 6-Phosphofructo-2-Kinase (PFKFB3) for the treatment of breast cancer. AACR. 76:2016.